HOME >> MEDICINE >> NEWS
Data supports extremely early intervention for multiple sclerosis patients

et will go on to develop typical MS. Consequently, a second occurrence of MS symptoms involving another part of the nervous system or definite new abnormalities that appear on magnetic resonance imaging (MRI) of the brain and spinal cord are required in order to make a definite MS diagnosis.

This study, involving patients from 32 sites across the U.S. over a five-year period, was designed to determine if much earlier treatment within a month of the appearance of initial symptoms and before a definite diagnosis had been made would delay the onset of new neurological symptoms compared to initiation of therapy more than two years after the onset of symptoms.

"The study actually evolved from an earlier investigation, known as the CHAMPS study," explains Kinkel. CHAMPS, a two-year blinded placebo controlled trial in which 383 MS patients were treated weekly with either Avonex or a placebo, found that those individuals who received Avonex experienced a 44 percent decrease in the rate of developing a second MS attack that would qualify them for a diagnosis of MS compared with the patients who received a placebo.

"We were extremely pleased with the outcome of the CHAMPS trial," notes Kinkel. "But we realized that because disabling MS symptoms such as difficulty walking and thinking that does not improve may not appear in patients for many years. We would have to conduct a much longer study to determine if Avonex actually slowed the progression of these debilitating symptoms."

To test the medication's long-term effectiveness, the study followed 203 patients, half of whom had been receiving Avonex from the onset of the CHAMPS trial (immediately after demonstrating MS symptoms) and half of whom began treatment with Avonex at a later point, following their second MS attack (or two or more years after their first attack). The study found that patients who began treatment with Avonex immediately after their first attack had a 35 perce
'"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
20-Sep-2003


Page: 1 2 3

Related medicine news :

1. Emergency department study supports giving dehydrated children fluids by mouth
2. Review supports link between HRT and stroke
3. Chamomile tea: New evidence supports health benefits
4. Social supports lessen effects of maltreatment on children vulnerable to depression
5. Study supports the use of mechanical assistance
6. Study supports aggressive treatment of heart patients with cholesterol-lowering medication
7. New data supports CellCepts position as a world leader in solid organ transplantation
8. NCI grant supports Jefferson trial to study test for colorectal cancer recurrence
9. Study supports new theory for nicotines protective effect against neurodegenerative disorders
10. New study supports use of PET scans in early diagnosis of Alzheimers disease
11. Contraception study supports convenience, simplicity

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... VA (PRWEB) , ... February 20, 2017 , ... Silverado ... Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, Virginia. ... 2018 on a site just outside of Old Town. , The three-story community ...
(Date:2/20/2017)... ... February 20, 2017 , ... Clearwave is the ... on the Posiflex XT-series of touch screen terminals. Both companies will be showcasing ... Florida. The terminal provider Posiflex is helping to bridge the gap between healthcare ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... as an employee health benefit for companies that want to help members of ... providers, employees will have access to Watson’s suite of oncology offerings for insights ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and ... Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New York ... needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in a ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Rosacea market? ...
(Date:2/20/2017)... Taiwan , Feb. 21, 2017 Taiwan ... leading provider of non-invasive vital signs sensing solutions, today ... industry,s first finger-free wrist pulse oximeter, the oCare TM ... the wearable healthcare and medical devices space.  ... 100, provides a non-invasive, simple and reliable method to ...
(Date:2/20/2017)...  This Report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing ... Forms, and Liquid & Semi-solid Dosage Forms. The report provides separate ... Japan , Europe , ... the full report: http://www.reportlinker.com/p04707109-summary/view-report.html ... Annual estimates and forecasts are provided for ...
Breaking Medicine Technology:
Cached News: